Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.
The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.
Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.
Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.
The firm maintained a hold rating and price target of AU$0.72 on Proteomics.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。